Purpose Unequal access to health care may be a reason for shorter survival among Black patients with renal cell carcinoma (RCC) than among their White counterparts. No studies have investigated survival disparity among RCC patients in an equal-access health care delivery system. This study aimed to examine racial differences in survival among clear cell RCC patients in the Department of Defense's (DoD) Military Health System (MHS), which provides equal access to care to all persons. Methods The study used the DoD's Automated Central Tumor Registry to identify 2056 White patients and 370 Black patients diagnosed with clear cell RCC between 1988 and 2004. The subjects were followed through 2007 with a median follow-up time of 4.8 years. Kaplan-Meier survival curves were compared and a Cox model was used to estimate the hazard ratios (HRs) associated with survival by race. Results During follow-up, 1,027 White and 158 Black patients died. The Kaplan-Meier curves showed that Black patients had more favorable overall survival than did White patients (log rank p = 0.031). After adjustment for demographic, tumor, and treatment variables, the Cox model showed no statistically significant racial difference overall (adjusted HR 1.07, 95 % CI 0.90-1.28) or stratified by age, sex or tumor stage. However, among patients who did not undergo surgery, Black patients had poorer survival than White patients. Conclusions The lack of racial difference in survival among RCC patients in the MHS may be related to equal access to health care. Improved access could reduce the survival disparity among RCC patients in the general population.
Introduction
In 2015, approximately 61,560 cancers of the kidney and renal pelvis will be diagnosed in the USA, and 14,080 deaths due to these cancers will occur [1] . Nearly 90 % of these tumors are renal cell carcinomas (RCC) [2] . RCC is the third leading cause of death among genitourinary malignancies and is the most lethal urologic malignancy [3, 4] . Research has shown that Black patients with RCC tend to have poorer prognosis and shorter overall survival than their White counterparts [5] [6] [7] [8] . A recent Surveillance, Epidemiology, and End Results (SEER) analysis reported that Black persons with RCC consistently had higher allcause mortality rates than White persons in the general population [5] . Similar overall survival disparity among RCC patients was observed in several other studies based on earlier SEER data [7, 8] and statewide cancer registry data [6] . The reasons for this disparity in mortality are unknown but may be related to racial differences in access to health care and treatment [5] [6] [7] [8] [9] [10] , differences in quality of care received [5, 7] , patients' attitudes toward and beliefs in treatment decisions [5, 7] , comorbid conditions [5, 7, 8, 11] , and stressful life events associated with socioeconomic status [5] [6] [7] .
Among factors that may be associated with racial disparity in cancer outcomes, unequal access to health care may be a major one [5] [6] [7] [8] [9] . Inadequate access to health care by racial minorities may result in delayed diagnosis, advanced tumor stage, and suboptimal treatment [12] , and may result in poor survival. In the general population, Black persons are more likely than White persons to have inadequate insurance coverage and are more likely to receive lower quality of care [13, 14] . Thus, Black persons are less likely to receive timely and optimal cancer treatments [13, 14] , which may result in a higher risk of having unfavorable disease outcomes. In an equal-access system, different racial groups have similar level of access to medical care, presumably with similar quality of care. Identification of whether there are racial differences in outcome in an equal-access system is important for evaluating the role of equal access to care in racial disparities. Previous research has shown that, with equal access to care and treatment, Black and White persons have similar survival experiences for lung cancer [15] [16] [17] , colon cancer [18, 19] , and prostate cancer [20] . To date, there has been no research in an equal-access system to investigate survival among patients with RCC.
The Department of Defense's (DoD) Military Health System (MHS) provides equal health care access to military service members, retirees, and their dependents. Therefore, the MHS offers an excellent resource for examining whether racial disparity in RCC survival exists. In addition to assessing whether there were differences in survival, we also evaluated whether the racial groups differed in survival by demographic variables, tumor characteristics, and treatments.
Materials and methods

Sources of data
The sources of data have been described previously [16] [5, 21] . We confined analysis to clear cell RCC because of the relatively small numbers of patients with other histologic types and considerations in minimizing potential confounding by histology [21, 22] . Cancer site and histology were classified using the topography (C64.9) and morphology codes (8310-8312) of the International Classification of Diseases for Oncology, third edition (ICD-O-3) [23] . Patients with history of another primary cancer(s) were excluded to minimize the potential effect on survival of other cancers. A total of 2426 patients were included in the final analysis. Data through 31 December 2007 were included in the analysis.
Statistical analysis
The study outcome was all-cause mortality. The observed survival time was calculated as the difference between date of diagnosis and date of death for persons who died during the study period. For persons who did not die during the study period, survival time was censored at the date of last contact or the end of the study, 
Results
The study participants consisted of 2056 White patients and 370 Black patients (Table 1) . Compared with White patients, Black patients tended to be younger, with 31.9 % of Black patients diagnosed before age 50 years compared with 21.4 % of White patients (p \ 0.0001) ( Table 1) . Black patients were more likely to be non-Hispanic (p \ 0.0001), divorced or separated (p = 0.003), and in the Army (p = 0.0003). Although not statistically significant, Black patients were more likely to be diagnosed at localized stages (64.9 versus 58.2 %) and to have smaller tumors (B30 mm) (p = 0.0083), but there was no significant difference in tumor grade distribution (p = 0.1888). There were no significant racial differences in sex, active duty status, receipt of surgery, receipt of chemotherapy, receipt of radiation therapy, or recurrence. The results remained similar when age was standardized (Table 1) . During the follow-up period, 1030 White patients and 158 Black patients died. The Kaplan-Meier curve (Fig. 1) showed significantly better overall survival among Black than White patients (log rank p = 0.031). Table 2 
Discussion
In this study, we found no statistically significant racial differences in survival among patients with clear cell RCC after adjustment for demographic, tumor, and treatment factors. This finding was generally observed across subgroups defined by age, sex or tumor stage.
In prior studies, Black persons have been consistently reported to have poorer overall survival than White persons in large population-based studies [5] [6] [7] [8] 10] . In a study using the SEER-Medicare database, 964 Black and 10,482 White RCC patients aged 65 years and older were identified. After adjustment for demographic variables and cancer prognostic factors, overall survival was poorer among Black than White persons [7] . Poorer relative survival among Black persons was also observed in a study using data from the California Cancer Registry of 39,432 patients with RCC diagnosed between 1988 and 2004 [6] . In addition, a SEER-based study of RCC [8] reported poorer overall survival among Black patients than their White counterparts. While this racial disparity may be related to multiple factors such as quality of care [5, 7] , health care behavior and beliefs [5, 7] , comorbidity [5, 7, 8, 11] , social environment [5, 7] , and biological predisposition [6, 24] , accessibility to health care [5] [6] [7] [8] [9] [10] may be most influential. Poorer access to health care by racial minorities has been frequently associated with delayed diagnosis, advanced disease stage, suboptimal treatment, and poor prognosis [12, [25] [26] [27] . A recent study based on SEER data of nearly 40,000 RCC patients [5] diagnosed from 1992 to 2007 found that Black persons consistently had higher all-cause mortality than White persons, even though both groups had the same tumor stage, tumor size, or surgical treatment. It should be noted, however, that the study only conducted univariate analyses with stratification on a single factor such as tumor stage. In addition, even among persons with tumors of the same stage who receive surgery, race may be a determinant of timing, interval, frequency, and quality of various treatments including surgery, follow-up, and surveillance. While equal access does not necessarily mean equal utilization of medical care, smaller or no difference in survival between racial groups in an equal-access system would suggest that equal access may reduce racial disparities. Indeed, persons with common cancers have been observed to have similar survival experiences in studies Table 1 conducted in equal-access systems [15] [16] [17] [18] [19] [20] . To the best of our knowledge, our study is the first one among RCC patients in such a system. Our study found no overall racial difference in survival after adjustment for demographic, tumor, and treatment factors. The results suggest that the survival disadvantage among Black persons in the general population may be associated with poorer access to care. Although no overall racial differences were observed in our study, we did find that Black persons who did not receive surgery experienced worse survival than their White counterparts. While the hazard ratios between subgroups by surgery were not significantly different, some racial disparity may exist. Patients who do not receive surgery are more likely to have renal failure at diagnosis due to the severity of the underlying kidney disease [28, 29] . It is possible that the survival difference observed in this stratum may reflect a larger proportion of Black persons with renal failure at diagnosis. In contrast to our study, however, a study in a Medicare population [7] found that Black persons who did not receive surgery had better crude survival than did White persons, but the difference in survival was reduced substantially after adjustment for cancer stage, tumor size, and demographic variables. Nevertheless, in a recent SEER study [5] without adjustment for tumor stage and other factors, among persons who received surgery, Black persons had poorer survival than White persons. While the reasons for the differences in results between that study and our study are not clear, we do not exclude the possibility that the racial disparity in allcause death might result from differences in factors not included in the current study, such as comorbid conditions or timing and frequency of treatment of renal cancer.
Compared with White patients, Black patients in the current study were diagnosed at earlier stages and with smaller tumors, characteristics that are frequently linked to better prognosis. Earlier stage at diagnosis among Black persons compared with White persons has also been consistently observed in previous studies of the general population [5-8, 10, 30] . Better survival among Black patients in our study might result from diagnosis at earlier tumor stages because the survival advantage of Black patients was no longer observed after adjustment for tumor stage and other variables. However, in previous studies in the general population, the poorer survival of Black persons persisted despite their earlier tumor stage [5] [6] [7] [8] 30] . Perhaps, in the general population, the survival benefit of early stage is not sufficient to counterbalance the disadvantage of other unfavorable factors, including limited access to health care. This study has several strengths. First, the study was performed in an equal-access health care system, thus the impact of unequal access on survival disparity is largely minimized or controlled, which is unlikely to exist in studies of general population. Second, as a registry-based study, the availability of demographic, tumor, and treatment data from the DoD Cancer Registry allows for control for confounding and permits stratified analysis to identify racial disparity in subgroups. It should be noted, however, that we had limited statistical power in certain subgroup analyses due to relatively small numbers. Also, data were not available to address the role of other potential factors (such as comorbid conditions, social economic status, life styles, health care behaviors, etc.) on survival disparity in RCC patients, and renal cancerspecific death cannot be evaluated.
To the best of our knowledge, this is the first study of survival among RCC patients in an equal-access system. We found no racial differences in overall survival among Black and White patients with clear cell RCC. Our results suggest that unequal access to health care plays an important role in survival disparity and that better access to health care could reduce this disparity in the general population.
